Berenberg Bank Lowers Hikma Pharmaceuticals (LON:HIK) Price Target to GBX 2,300

Hikma Pharmaceuticals (LON:HIK) had its target price lowered by stock analysts at Berenberg Bank from GBX 2,510 to GBX 2,300 in a research report issued to clients and investors on Thursday,London Stock Exchange reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price objective points to a potential upside of 45.39% from the company’s current price.

Several other analysts have also issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a report on Friday. Peel Hunt reiterated a “buy” rating and set a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of GBX 2,416.

Hikma Pharmaceuticals Stock Performance

Shares of LON:HIK traded up GBX 60 during midday trading on Thursday, hitting GBX 1,582. The company’s stock had a trading volume of 1,155,675 shares, compared to its average volume of 1,297,659. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock’s 50 day simple moving average is GBX 1,734.94 and its 200 day simple moving average is GBX 1,896.07. The stock has a market capitalization of £3.50 billion, a price-to-earnings ratio of 9.47, a PEG ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,522 and a fifty-two week high of GBX 2,360.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Laura Balan Balan purchased 3,500 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah acquired 315,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was bought at an average price of GBX 1,601 per share, with a total value of £5,043,150. In the last three months, insiders have acquired 332,500 shares of company stock worth $533,130,500. Insiders own 17.77% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.